The US Food and Drug Administration has approved Lembaz for infantile-onset Niemann-Pick disease type C, after evidence showed it cut the risk of death by more than half and extended median survival by years.
By The BNN Media
The Best News Network
News Beyond the Borders
Washington, United States — The US Food and Drug Administration (FDA) has approved Lembaz (adrabetadex), the first medicine shown to help patients with infantile-onset Niemann-Pick disease type C live longer, offering new hope to families facing one of the rarest and cruellest childhood diseases.

The Approval
The FDA announced the approval on 17 November 2026. Lembaz, made by Beren Therapeutics, is approved to reduce the risk of death in adults and children who weigh at least 7 kilograms (about 15 pounds) and have Niemann-Pick disease type C (NPC) with neurological symptoms that began before the age of six — the form known as infantile-onset NPC.
It is the first treatment for the disease shown to improve survival. An earlier NPC treatment was approved in September 2024, but Lembaz is the first that has demonstrated it can extend patients’ lives.
The drug received the FDA’s Breakthrough Therapy designation, and Beren received a priority review voucher with the approval. The company said Lembaz will be available at treatment sites across the United States in early December.
For a disease that has long had almost nothing to offer families, this is the first approval that changes the prognosis itself.
A Disease With Almost No Options
Niemann-Pick disease type C is a rare, inherited genetic disorder in which cholesterol and other fats build up inside the body’s cells, damaging the brain, liver, spleen and other organs. In its infantile-onset form, neurological symptoms appear in early childhood, and the disease is usually fatal in childhood or early adolescence.
Children with the condition develop progressive problems with movement, speech, swallowing and thinking. There is no cure, and until now treatment has been limited to managing symptoms and, in some cases, the off-label use of an older drug, miglustat, which is not approved for NPC.
That is what makes the Lembaz approval significant: it is the first medicine that addresses the underlying defect — the faulty cholesterol trafficking inside cells — rather than only treating the symptoms it causes.
Families have waited years for a treatment that tackles the cause, not just the consequences. Lembaz is the first to do that.
The Survival Evidence
The approval rests on survival data that the FDA judged strong enough to support it. The agency evaluated 36 patients with infantile-onset NPC treated with adrabetadex across three clinical studies and an expanded access programme, compared with a matched external control group.
Treatment was associated with a 55 per cent reduction in the risk of death. Median overall survival was 8.5 years among treated patients, compared with 4.9 years among the controls — a difference of more than three and a half years. The benefit was seen regardless of whether patients were also taking miglustat off-label.
Adrabetadex is a formulation of 2-hydroxypropyl-beta-cyclodextrin, a compound that helps mobilise the cholesterol trapped inside cells. It is given by intrathecal injection — into the fluid around the spinal cord — every two weeks, by trained clinicians.
A 55 per cent lower risk of death, and years of extra life, in a disease where children once had almost no time at all: that is the measure of this approval.

The Hearing Warning
The approval comes with a serious warning that families and doctors will need to weigh carefully. Lembaz carries an FDA boxed warning — the agency’s strongest — for hearing impairment, including permanent hearing loss.
Hearing loss ranging from mild to profound has occurred in some patients, including some whose hearing was normal before treatment. Dosing is therefore adjusted on the basis of repeated hearing tests, with baseline audiology checks and regular retesting, and dose increases are stopped when hearing thresholds shift beyond set limits.
Other reported effects include ataxia (problems with coordination) and fatigue in the days after each dose. The treatment must be given by trained providers, and the hearing-monitoring regime is part of the approval itself, not an optional extra.
The drug offers years of life — but at a real cost to hearing, which is why the FDA has made regular hearing tests a condition of its use.
The Caveats
The approval is not without controversy among specialists, and the draft of this report should be read with its limits in mind.
The survival evidence rests on a comparison with matched external controls, not a randomised trial — a weaker form of evidence, though the FDA determined that the comparison served as the adequate and well-controlled study supporting approval. The company’s announcement did not report patient numbers, length of follow-up or confidence intervals in full.
An earlier survival analysis, presented in March 2026, compared 72 treated children with 119 matched controls and reported a 71 per cent lower risk of death and five-year survival of 84 per cent versus 42 per cent. That analysis differs from the one reflected in the approval, and the two sets of figures should not be mixed.
The only randomised trial of the drug lasted 12 months, and its results led the FDA to rescind the drug’s first Breakthrough Therapy designation — a history that specialists have noted in coverage of the approval.
The approval is real, and the survival benefit is real — but it rests on a comparison with past patients, not a head-to-head trial, and that is a limit readers should know about.
What Happens Next
Beren Therapeutics said Lembaz will be available at commercial treatment sites across the United States in early December. The company plans to meet the FDA to discuss the next regulatory steps, and further studies will be needed to confirm the benefits — as is normal for approvals based on this kind of evidence.
For the families of children with infantile-onset NPC, the practical question now is access: which centres will offer the fortnightly spinal injections, how hearing monitoring will be organised, and how the treatment will be funded. Those details were not part of the approval announcement.
What is certain is that a disease which once offered families almost no hope now has a first treatment that has been shown to extend life. For a rare-disease community that has campaigned for years for research into NPC, that alone is a landmark.

A first treatment that extends life is a landmark for any rare disease. For children with Niemann-Pick type C, it is the first time the future has looked longer than the past.
By The BNN Media
The Best News Network
News Beyond the Borders
Sources: US Food and Drug Administration (press announcement, 17 Nov 2026); Beren Therapeutics (BusinessWire); Pharmacy Times; Neurology Live; Contemporary Pediatrics.